• Understanding the new regulatory environment
• How will the reforms affect generic manufacturers?
• What are the benefits for the public?
• In what direction is the legislation moving?

• Analysing effects of PBS reform on F1, F2A & F2T medicines
• Comparing retail pharmacy profitability pre and post reforms
• The role of generic medicines in offsetting price cuts

• Examining the generic take-up in global markets
• Investigating the Australian Generic Policy: why is generic
  substitution in Australia so low?
• Global policies adopted and incentives placed on doctors,
  pharmacists and patients
• Fostering the diffusion of Generics: what institutional factors
  and incentives need to be included?

• Consolidating the international market: how will it look in the
  next few years?
• Emerging threats to the global generics market
• Novel investment prospects: key regions of growth

• What’s the value of a large number of players in the market?
• Generic prospects arising from the Australia-India Trade
  Agreement
• Impact of mergers & acquisitions between Australian & Asian
  companies on the market
• How global does Australia need to be to survive?

• Alignment with a changing pharmacy landscape
• Differentiating yourself from the competition: a diversified
  business model
• Drivers for profit sustainability

Discussion 1:Working in partnership with distribution and supply chain operators
Michael Ison, Business Unit Director, DHL


Discussion 2: Collaborating with CROs
Alek Safarian, CEO, Novotech

• Predicting growth areas as blockbuster drug supply declines
• Differentiation strategies: influencing consumer selection
  through a generics-plus portfolio
• Supergenerics – the most effective value-add properties

• Do traditional pharma marketing strategies translate?
• Learning commercialisation lessons from other markets
• Is first-to-market the best strategy?
• Maximising the benefits of outsourcing

• Are generics impacted by negative marketing and the press?
• The Government’s role in marketing generics to the public
• Enabling informed consumer choices: solutions to improve
  communicating information about generics

• International patent and regulatory status
• Drivers and resisters to biosimilar growth
• Do increased regulatory requirements translate to reduced
  market attractiveness?

• Optimising the development process to mitigate costs
• Exploring pricing alternatives to reduce overheads
• Entry strategies for bringing a biosimilar to market
• The importance of proximity of manufacturing sites to market
  location: learning lessons from China and India

• Market potential: does it translate from overseas to Australia?
• What will be the legislative requirements?
• Business case for getting involved: regulatory and marketing
  challenges vs. ROI
• How models will evolve following the introduction of
  biosimilars

  Tim Oldham, President Asia Pacific, Hospira
  Dr John Donohoe, Head of the Management Co-Ordination Unit, Drug Safety and Evaluation Branch, TGA
  Dr Balasubramaniam, Head of Operations, SciGen Group
  Michael Schildkraut, General Manager, Sandoz

• Novel methods of CRM: working with pharmacists in the
  absence of financial incentives
• Alternative strategies to seal pharmacy partnerships
• The future of pharmacy retailing

• Promoting generic alternative to patients: what do
  pharmacists need to know?
• The importance of educating patients about generic
  substitution
• Overcoming issues surrounding prescribing by brand name

• What do pharmacists want and need from generic
  manufacturers?
• Challenges faced when promoting generics to patients
• What do pharmacists think of the PBS reforms?
• Improving current distribution systems

• Global trends in IP strategy development
• Developing independent strategies for Australia
• Linking market authorisation to patent rights
• Information sources for strategy development
  
  
  Leighton Howard, Managing Director, GenericsWeb

• Evergreening vs. innovation: do patents encourage or stifle
  R&D?
• Impact of increased patent lengths on the PBS spend
• Preventing the exploitation of patents through evergreening
• Establishing evergreening guidelines: what novel properties
  warrant patent extensions?

• Examining the legal background
• Investigating the ongoing impact on the generics industry
  globally
• Understanding the related issue of obviousness
• Identifying key trends coming out of recent cases

• Examining the impact of the Free Trade Agreement
• Developments in global reform: how will the generics
  industry be affected?
• Legal challenges facing the Australian generics market today
• Maximising efficiency whilst working within the current
  legislative confines

• Which companies and regions are exhibiting the greatest
  strength?
• Emerging threats to the global generics industry
• Future of the government PBS legislation
• Impact of the wave of mergers and acquisitions: will there be
  only a few companies left?